Impact of Diagnosis-Related Groups (DRG) reform on cost homogeneity of treatment for patients with malignant tumours.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Neoplasms*/therapy ; Neoplasms*/economics ; Diagnosis-Related Groups*; Humans ; Male ; Female ; Middle Aged ; Hospitalization/economics ; China ; Medicine, Chinese Traditional/economics ; Medicine, Chinese Traditional/methods ; Immunotherapy/economics ; Immunotherapy/methods ; Aged ; Health Care Costs ; Adult

The cost fluctuations associated with chemotherapy, radiotherapy, and immunotherapy, as primary modalities for treating malignant tumors, are closely related to medical decision-making and impose financial burdens on patients. In response to these challenges, China has implemented the Diagnosis-Related Group (DRG) payment system to standardize costs and control expenditures. This study collected hospitalization data from patients with malignant tumors who received chemotherapy, radiotherapy, and immunotherapy at Hospital H from 2018 to 2022. The dataset was segmented into two groups: the intervention group, treated with traditional Chinese medicine (TCM) alongside standard therapies, and the control group, treated with standard therapies alone. Changes and trends in hospitalization costs under the DRG policy were analyzed using propensity-score matching (PSM), standard deviation (SD), interquartile range (IQR), and concentration index (CI). Findings showed a decreasing trend in the standard deviation of hospitalization costs across all treatment modalities. Radiotherapy exhibited the most significant decrease, with costs reducing by 2547.37 CNY in the control group and 7387.35 CNY in the intervention group. Following the DRG implementation, the concentration indexes for chemotherapy and radiotherapy increased, while those for immunotherapy did not exhibit this pattern. Costs were more concentrated in patients who did not receive TCM treatment. In summary, DRG reform positively impacted the cost homogeneity of inpatient treatments for malignant tumors, particularly in the control group not receiving TCM treatment. The effects of DRG reform varied across different treatment modalities. Although short-term fluctuations in hospitalization costs may occur, initial evidence during the study period shows the positive impact of DRG reform on cost homogeneity.
(© 2024. The Author(s).)

J Oncol Pharm Pract. 2021 Dec;27(8):2004-2006. (PMID: 34558362)
Ann Surg. 2022 Dec 1;276(6):e728-e734. (PMID: 33214485)
J Surg Res. 2021 Nov;267:9-16. (PMID: 34120017)
Health Policy. 2009 Oct;92(2-3):158-64. (PMID: 19361879)
Urol Pract. 2018 Sep;5(5):334-341. (PMID: 30746428)
Res Social Adm Pharm. 2021 Jul;17(7):1300-1305. (PMID: 33054991)
Med Care. 1980 Feb;18(2 Suppl):iii, 1-53. (PMID: 7188781)
J Hosp Med. 2017 Oct;12(10):818-825. (PMID: 28991947)
Medicine (Baltimore). 2024 Mar 15;103(11):e37385. (PMID: 38489691)
J Immunol Res. 2022 Mar 18;2022:8052212. (PMID: 35340585)
BMC Health Serv Res. 2021 May 24;21(1):496. (PMID: 34030683)
BJOG. 2018 Jun;125(7):829-839. (PMID: 29090498)
J Oncol Pract. 2015 Sep;11(5):391-5. (PMID: 26130817)
JAMA Intern Med. 2017 May 1;177(5):675-682. (PMID: 28288254)
Front Med. 2017 Jun;11(2):191-202. (PMID: 28349301)
Health Care Manage Rev. 2008 Oct-Dec;33(4):341-9. (PMID: 18815499)
J Health Organ Manag. 2020 Feb 08;34(3):295-311. (PMID: 32364346)
J Surg Res. 2018 Aug;228:299-306. (PMID: 29907225)
Clin Ther. 2020 Sep;42(9):1682-1698.e7. (PMID: 32747004)
BMC Health Serv Res. 2021 May 5;21(1):425. (PMID: 33952266)
BMJ Qual Saf. 2024 Aug 16;33(9):587-596. (PMID: 37336572)
J Healthc Eng. 2023 Oct 11;2023:9895186. (PMID: 37860400)
Health Serv Res. 2019 Feb;54(1):97-105. (PMID: 30318592)
Chin Med J (Engl). 2020 Oct 15;133(24):2987-2997. (PMID: 33065603)
Front Med (Lausanne). 2021 Jun 11;8:655231. (PMID: 34179041)
PLoS One. 2020 Oct 27;15(10):e0241179. (PMID: 33108373)
BMJ. 2013 Jun 07;346:f3197. (PMID: 23747967)
Hepatobiliary Surg Nutr. 2020 Dec;9(6):771-773. (PMID: 33299831)
Cancer Lett. 2019 Jun 28;452:66-70. (PMID: 30902563)
Future Oncol. 2022 Jan;18(1):93-104. (PMID: 34652217)
Am J Chin Med. 2020;48(7):1577-1592. (PMID: 33202152)
J Psychosom Res. 2012 Nov;73(5):383-90. (PMID: 23062813)
Theranostics. 2019 Oct 15;9(25):7772-7791. (PMID: 31695800)
J Ethnopharmacol. 2021 Jan 10;264:113249. (PMID: 32810619)
BMC Health Serv Res. 2023 Jun 24;23(1):688. (PMID: 37355657)
Med Decis Making. 2020 Feb;40(2):170-182. (PMID: 32065026)
Health Econ. 2013 Feb;22(2):234-42. (PMID: 22223593)
J Healthc Eng. 2021 Nov 22;2021:6158961. (PMID: 34853670)
Risk Manag Healthc Policy. 2021 Jun 01;14:2263-2276. (PMID: 34104017)
Future Oncol. 2021 Feb;17(4):455-469. (PMID: 33021099)
Medicine (Baltimore). 2019 Feb;98(7):e14468. (PMID: 30762764)
Comput Math Methods Med. 2020 Nov 1;2020:3189676. (PMID: 33204299)
Biosci Trends. 2021 Nov 21;15(5):283-298. (PMID: 34421064)
Hosp Health Serv Adm. 1988 Summer;33(2):263-9. (PMID: 10312525)
PLoS One. 2015 Apr 17;10(4):e0122695. (PMID: 25884623)
Health Econ Policy Law. 2010 Oct;5(4):459-79. (PMID: 20478106)
Health Policy Plan. 2009 May;24(3):209-16. (PMID: 19237388)
Rand J Econ. 2008 Autumn;39(3):790-821. (PMID: 19013864)
Front Immunol. 2021 Jan 21;11:609705. (PMID: 33552068)
Health Res Policy Syst. 2019 Dec 16;17(1):99. (PMID: 31842882)
Am J Chin Med. 2020;48(8):1731-1748. (PMID: 33308095)
J Am Coll Surg. 2006 Apr;202(4):565-76. (PMID: 16571423)
J Thorac Dis. 2020 Jul;12(7):3796-3803. (PMID: 32802459)
World J Clin Cases. 2020 Jun 26;8(12):2484-2493. (PMID: 32607325)
Spine (Phila Pa 1976). 2016 Jul 1;41(13):1111-1117. (PMID: 26780612)
Front Oncol. 2022 Sep 21;12:914591. (PMID: 36212482)
Clin Exp Neuroimmunol. 2017 Nov;8(4):318-326. (PMID: 29242717)

Keywords: China; Cost homogeneity; DRG; Hospitalization costs; Malignant tumours; Traditional Chinese Medicine

Date Created: 20240911 Date Completed: 20240911 Latest Revision: 20240916

20240916

PMC11390736

10.1038/s41598-024-71917-y

39261579